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Abbreviations 3 
cSCC   Cutaneous squamous cell carcinoma 4 
DOTAP 1,2-dioleoyloxy-3-trimethylammonium propane 5 
DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 6 
hBD-2  Human beta defensin 2 7 
IFNγ   Interferon gamma   8 
IL   Interleukin 9 
Keratin 17  KRT17 10 
LCNPs Liquid crystalline nanoparticles  11 
miRNA  MicroRNA 12 
MO  Monoolein 13 
siRNA  Short/small interfering RNA 14 
SNA-NC  Spherical nucleic acid-nanoparticle conjugates  15 
STAT3  Signal transduction and activator of transcription 3 16 
TACE  Tumour necrosis factor alpha (TNFα)-converting enzyme 17 
TGFβ   Transforming growth factor beta 18 
TIMP-3 Tissue inhibitor of metalloproteinase 3  19 
TNFα   Tumour necrosis factor alpha  20 
 21 
  22 
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Abstract 1 
There remains an unmet dermatological need for innovative topical agents that 2 
achieve better long term outcomes with fewer side effects. Modulation of the 3 
expression and activity of microRNA (miRNAs) represents an emerging translational 4 
framework for the development of such innovative therapies because changes in the 5 
expression of one miRNA can have wide-ranging effects on diverse cellular 6 
processes associated with disease. In this short review, the roles of miRNA in 7 
epidermal development, psoriasis, cutaneous squamous cell carcinoma and re-8 
epithelisation are highlighted. Consideration is given to the delivery of 9 
oligonucleotides that mimic or inhibit miRNA function using vehicles such as cell 10 
penetrating peptides, spherical nucleic acids, deformable liposomes and liquid 11 
crystalline nanodispersions. Formulation of miRNA-directed oligonucleotides with 12 
such skin-penetrating epidermal agents will drive the development of RNA-based 13 
cutaneous therapeutics for deployment as primary or adjuvant therapies for 14 
epidermal disorders. 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Introduction 1 
Few discoveries in recent bioscience history have had as wide-ranging an impact as 2 
the observation that small endogenous non-protein coding RNAs regulate the 3 
expression of multiple gene targets in diverse species. Following early reports by the 4 
Victor Ambros (1) and Gary Ruvkun (2) laboratories, the breakthrough came in 2001 5 
with 3 Science papers that showcased the widespread nature of microRNA (miRNA) 6 
expression in metazoan organisms (3-5). Since then, the number of microRNA-7 
related entries in PubMed has grown exponentially to over 64,000 (Fig. 1A).  8 
 9 
Fig. 1: Growth in the PubMed records returned using the search term (A) 10 
“microRNA” (A) or “microRNA and skin (B).   11 
The miRNA revolution stems from the ability of these small non-coding RNA 12 
(ncRNA) molecules, typically ~22 nucleotides long, to regulate post-transcriptional 13 
expression across most of the genome, thereby fine-tuning numerous pathways that 14 
control cell behaviour (6, 7). Small ncRNAs are defined as being less than 200 nt 15 
long, and in addition to miRNAs, include small-interfering RNAs (siRNAs), piwi-16 
interacting RNAs (piRNAs), small nuclear RNAs (snRNAs) and small nucleolar RNA 17 
(snoRNAs) (8-10).  18 
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More recently, long ncRNAs (defined as >200 nt long) have garnered 1 
attention as central regulators of physiological and pathological processes, despite 2 
being expressed at 15-230 lower levels than protein coding transcripts (8). One such 3 
lncRNA, PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress), has 4 
long been associated with psoriasis, a debilitating skin disorder characterised by 5 
complex interplay of cytokines from immune and skin cells (11, 12). Recent efforts 6 
have defined a plethora of differentially expressed lncRNAs psoriatic skin (13-15) 7 
and in cutaneous squamous cell carcinoma (cSCC) (16-18). The roles of lncRNA in 8 
epidermal homeostatic and skin diseases have been very recently been reviewed by 9 
Botchkareva (19) so will not be considered further here.   10 
As the largest and most accessible organ of the body, the skin represents a 11 
major tissue for pharmacologic drugs targeting cutaneous disorders as well as 12 
systemic delivery of active agents. The goal of this short review is to highlight the 13 
emerging consensus on the global mechanism of miRNA action, the roles of miRNA 14 
in development and disease with reference to the epidermis, the outer layer of the 15 
skin. The translational prospects for topical delivery of RNA-directed oligonucleotides 16 
for skin disorders will focus on cell penetrating peptides (CPPs), spherical nucleic 17 
acid (SNA)-gold nanoparticles, deformable liposomes and liquid crystalline 18 
nanoparticles (LCNPs). Nanoparticles based on natural or synthetic polymers such 19 
as chitosan or poly(lactide-co-glycolic acid) will not be considered herein as they 20 
have received little attention for cutaneous oligonucleotide delivery and have been 21 
reviewed elsewhere for dermatological disorders (20). For broader consideration of 22 
the issues associated with the design and delivery of oligonucleotide-based therapy 23 
to diverse tissues, see the recent review by Juliano (21).   24 
 25 
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MicroRNA Biogenesis 1 
Mature miRNAs arise from hairpin precursors (pre-miRNAs) which are themselves 2 
largely derived from intergenic or intronic regions of coding and non-coding 3 
transcripts as reviewed elsewhere (22-24). Gene repression by miRNAs is mediated 4 
by the RNA-induced silencing complex (RISC), the assembly of which has been 5 
reviewed recently (25). In its mature form, the RISC consists of a single-stranded 6 
mature miRNA bound to an Argonaute (AGO) protein, of which there are four 7 
paralogs in human cells (AGO1–AGO4). By guiding AGO proteins to the 3’ 8 
untranslated region (3’ UTR) of target mRNA, the miRNA facilitates sequence-9 
specific repression of gene output (6, 22-26).  Recent structural studies have yielded 10 
exquisite insight into the mechanistic and conformational basis for guide miRNA 11 
binding to AGO2 and target RNAs (27, 28).  12 
 13 
Mechanisms of microRNA action 14 
Mature miRNA duplexes consist of a guide strand which mediates RISC action and a 15 
passenger or minor strand (miRNA*) that was considered to be degraded (29). 16 
However, recent studies have shown miRNA* also regulate gene expression via 17 
RISC-dependent binding to the 3’UTR of mRNA transcripts (30, 31). For this and 18 
other reasons (32, 33) mature miRNAs are now designated miR-#-5p or miR-#-3p 19 
according to the precursor hairpin arm from which they arise. 20 
Early studies indicated that a given miRNA can downregulate the expression 21 
of hundreds of target genes at the mRNA and protein levels (34-37). What has been 22 
somewhat controversial is whether such miRNA-dependent attenuation of gene 23 
output relies primarily on destabilisation and degradation of mRNA or on inhibition of 24 
translational (38). Several studies suggested miRNAs function by blocking initiation 25 
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or elongation phases of translation (39-43) and that, at least in HeLa cells,  1 
translational inhibition was the dominant effect of miRNAs (44, 45). However, the 2 
Bartel group observed little change in the translational efficiency of ribosomes on 3 
target mRNAs in HeLa cells, accounting for around 16% of the observed miRNA-4 
dependent repression. In contrast 84% of miRNA-mediated gene repression could 5 
be attributed to mRNA destabilisation (46). Subsequent investigations on cell lines, 6 
primary macrophages, mouse liver and primary B cells revealed that while 7 
translational repression dominates miRNA action immediately following robust 8 
miRNA induction, this is soon subsumed within a much greater mRNA destabilization 9 
effect that maintains steady-state repression (47).   10 
 11 
MicroRNAs and epidermal development  12 
The epidermis forms the outer part of the skin and consists predominantly of 13 
keratinocytes stratified from a basal layer of viable cells to an outermost layer of 14 
terminally differentiated keratinocytes. Studies returned by PubMed in relation to 15 
“microRNA and skin” have also grown exponentially over the last decade, 16 
showcasing the efforts that have been made to define the contributions of 17 
microRNAs to normal and pathological skin biology (Fig. 1B). From a developmental 18 
perspective, studies with mouse models have revealed that miR-203, miR-205 and 19 
miR-214 function as central controllers of epidermal morphogenesis. Several 20 
independent laboratories revealed that by downregulating the stem-cell associated 21 
transcription factor p63 along with other targets, miR-203 supports the initial 22 
commitment of embryonic stem cells to the keratinocyte lineage and bolsters the 23 
transition from proliferation to differentiation during stratification of the epidermis (48-24 
51). Loss of miR-205 led to derepression of phosphatases and other antagonists of 25 
Topical microRNA delivery for epidermal disease  
 
8 
 
the pro-survival protein Akt, resulting in a dramatic reduction in Akt activation in 1 
interfollicular progenitors and HFSCs (52). Hence the main function of miR-205 2 
appears to be maintenance of the proliferative capacity of basal cells in the nascent 3 
epidermis, hair follicle stem cells (HFSCs), outer root sheath, oesophagus and 4 
tongue (52). 5 
For miR-214, studies on transgenic mice have revealed multiple roles in the 6 
regulation of both embryonic hair follicle development and postnatal hair cycling (53). 7 
Keratinocyte-specific overexpression of miR-214 reduced proliferation of hair matrix 8 
cells and interfollicular keratinocytes, leading to thinner hair shafts and thinner 9 
epidermises, respectively (53). For further details on miRNA functions in skin 10 
development, see the excellent review by Yi and colleagues (54).  11 
Mouse studies have provided valuable insights concerning miRNA function in 12 
the developing epidermis. However, little consideration has been given to concerted 13 
efforts to use human cell and tissue models to uncover similar understanding of 14 
miRNA function. Ablation or ectopic expression of miRNAs in human induced 15 
pluripotent stem cells (hiPSCs) could provide a distinctive framework for 16 
characterising miRNA function in epidermal stratification and folliculogenesis, given 17 
that both mouse and human pluripotent SCs have been differentiated into 18 
multipotent keratinocytes that generate interfollicular keratinocytes, stratified 19 
epidermal equivalents and hair follicle cells (55-60). With over 700 hiPSC lines now 20 
available from the Human Induced Pluripotent Stem Cells Initiative (61), the path is 21 
clear for renewed efforts to decipher miRNA function using these cell lines as an 22 
alternative to mouse-based studies. Importantly, miRNA expression can be silenced 23 
in pluripotent SCs using transcription activator-like effector nucleases (TALENs) (62, 24 
63) or with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 25 
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and CRISPR-associated protein 9 (Cas9) nuclease gene editing (64, 65). Therefore, 1 
CRISPR-Cas9 reagents can be introduced into iPSCs using nucleofection or non-2 
lipid based chemical transfection with GeneJuice® (66, 67). The utility of CPPs and 3 
SNAs in delivery of TALEN and CRISPR-Cas9 reagents to iPSCs for subsequent 4 
differentiation into epidermal keratinocytes or hair follicle cells for ‘omics studies, 5 
morphometric assessment, drug screening and exposome analyses (68) warrants 6 
detailed investigation. 7 
 8 
MicroRNAs and psoriasis 9 
The major inflammatory molecules associated with epidermal inflammation and 10 
hyperplasia in psoriasis include interferon gamma (IFNγ), tumour necrosis factor 11 
alpha (TNFα), transforming growth factor beta (TGFβ) and interleukins (ILs) 12 
including IL-1, IL-17 and IL-22). Medium-scale and comprehensive screens revealed 13 
multiple miRNAs were dysregulated in psoriasis (69, 70), among which miR-21-5p 14 
functions as key mediator of epidermal inflammation (71). As illustrated in Fig. 2, 15 
miR-21-5p downregulates tissue inhibitor of metalloproteinase 3 (TIMP-3) in 16 
keratinocytes, as reported in several independent studies (71-73). The subsequent 17 
elevation of tumour necrosis factor alpha (TNFα)-converting enzyme (TACE; also 18 
known as ADAM17) activity results in enhanced release of soluble TNFα from 19 
keratinocytes to promote epidermal inflammation (71, 74). Notably, the depletion of 20 
TIMP-3 in a psoriasis-like mouse and in patient-derived xenografts on 21 
immunodeficient mice was reversed using anti-miR-21 oligonucleotides and this was 22 
associated with downregulation of inflammatory cytokines including IL-17, IL-23 and 23 
TNFα (71). Importantly, epidermal thickness of the xenografts was reduced by 24 
intradermal injection of anti-miR-21 every 48 h for 30 days. However, this decrease 25 
Topical microRNA delivery for epidermal disease  
 
10 
 
in epidermal thickness was observed in 8 out of 11 psoriasis cases (73%), leaving 1 
open the question of what factors precluded anti-miR-21 efficacy in the non-2 
responders.   3 
 4 
 5 
 6 
 7 
 8 
Fig. 2: Schematic depiction of a miRNA-21-dependent inflammation pathway. 9 
Elevation of miR-21 through mechanisms that are yet to be fully defined in 10 
keratinocytes leads to post-transcriptional repression of TIMP-3. Unfettered from 11 
TIMP-3 inhibition, TACE activity is enhanced, boosting the processing of 12 
transmembrane TNFα precursor into the soluble form that promotes inflammation 13 
through the TNFα receptor. 14 
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Interestingly, elevated levels of miR-21-3p have also been linked to skin 1 
inflammation (75). As the passenger or minor strand of the pre-miR-21 duplex, miR-2 
21-3p appeared to be around 1,000 times lower than miR-21-5p levels in the mouse 3 
epidermis. Nevertheless, pharmacologic or UV-dependent activation of the 4 
peroxisome proliferator-activated receptor (PPARβ/δ) nuclear hormone receptor led 5 
to a significant increase of miR-21-3p levels in mouse skin and the HaCaT 6 
keratinocyte cell line (75). In psoriatic skin, miR-21-3p was raised almost 4-fold 7 
compared to healthy skin (75). Importantly, although these observations were made 8 
using a rather small cohorts (n ≥ 4 independent biopsies) earlier work by Bowcock 9 
and colleagues had observed an almost 9-fold increase in miR-21-3p levels in 10 
lesional psoriatic skin compared to healthy skin, using 24 and 20 independent 11 
biopsies, respectively (70). Thus elevation of miR-21-3p appears to be strongly 12 
associated with psoriasis. Whether inhibition of miR-21-3p ameliorates psoriasiform 13 
inflammation remains to be seen. Nonetheless, topical anti-miR-21 oligonucleotides 14 
may need to target both miR-21-5p and miR-21-3p in the psoriatic epidermis for 15 
maximal therapeutic efficacy.  16 
The relationships between cytokines and miRNA dysregulation in 17 
keratinocytes have not been fully defined. That said, TGFβ1 has been shown to 18 
promote miR-21-5p and miR-21-3p expression in HaCaT keratinocytes (72, 73, 75-19 
77). Furthermore, miR-31 was induced by TGFβ1 in primary human keratinocytes, 20 
but not significantly changed by TNFα, IL-22, IL-6 or IFNγ (78). This contrasts with 21 
recent work by Wang and collaborators, who showed that each of these four 22 
cytokines could elevate miR-31 levels in primary keratinocytes by ≥2 fold, depending 23 
on concentration (79). In any case, levels of miR-31 were significantly elevated in 24 
psoriatic biopsies (78, 79). Importantly, inhibition of miR-31 reduced the basal and 25 
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TNFα-dependent expression of inflammatory cytokines and chemokines in human 1 
keratinocytes and reduced epidermal thickening and keratinocyte hyperproliferation 2 
in the imiquimod mouse model (78, 79). Taken together, these studies also suggest 3 
miR-31 functions within a positive feedback loop in keratinocytes: IL-6 activates NF-4 
κB to drive miR-31 expression and miR-31 represses serine/threonine kinase 40 5 
(STK40), a suppressor of NF-κB-dependent transcription to further enhance miR-31 6 
levels. It will be interesting to evaluate this hypothesis and define the implications of 7 
such a regulatory loop quantitatively. 8 
 The morphological alterations associated with the psoriatic epidermis are 9 
strongly linked to IL-22 activity (80). Little is known about the impact of IL-22 on 10 
keratinocyte miRNA expression. We have shown that IL-22 induces miR-184 in 11 
reconstituted human epidermis and in HaCaT keratinocytes, as does oncostatin M 12 
(81). Inhibition of the JAK/STAT pathway abrogated the cytokine-dependent 13 
expression of miR-184. Interestingly, we demonstrated the RISC effector AGO2 was 14 
downregulated by miR-184, suggesting a miR-184:AGO2 axis of dysregulation in 15 
psoriasis AGO2 (81). However, the extent to which miR-184 modulates epidermal 16 
homeostasis is unclear though recent studies on HaCaT keratinocytes suggest that 17 
miR-184 stimulates keratinocyte proliferation and reduces apoptosis (82). Beyond 18 
miR-184, IL-22 has also been shown to promote the expression of miR-197 in 19 
keratinocytes, and this was associated with increased binding of STAT3 to the miR-20 
197 promoter (83).    21 
Interestingly, miR-146a was among the first miRNAs found to be elevated in 22 
psoriatic skin (69). Evidence from the Sonkoly and Pivarcsi group indicated that Toll-23 
like receptor (TLR) ligands induced a sustained increase in miR-146a in 24 
keratinocytes, parsimoniously, to downregulate the expression of inflammatory 25 
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chemokines such as IL-8 and CCL-20 (84, 85). The picture that emerges is one in 1 
which miR-146a dampens TLR-dependent epidermal inflammation by suppressing 2 
TRAF6 (TNF receptor-associated factor 6) and IRAK1 (IL-1 receptor-associated 3 
kinase 1) consistent with early work by Baltimore and colleagues (86). Attenuation of 4 
TRAF6 and IRAK1, both of which mediate TLR signalling, in turn impaired activation 5 
of the nuclear factor kappa B (NF-κB) transcriptional programme and the recruitment 6 
of inflammatory cells (84, 85). More recent work showed miR-146a induction in 7 
keratinocytes exposed to IL-17, a central driver of psoriatic inflammation in the skin 8 
(87). Activation of NF-κB, expression of IL-8 and the ability of keratinocytes to attract 9 
neutrophils was abrogated in cells loaded with a synthetic miR-146a mimic, 10 
presumably due to downregulation of TRAF6, which is known to mediate IL-17A 11 
signalling to NF-κB (88, 89). Importantly, intradermal injection of the miR-146a mimic 12 
into mouse blocked the development of psoriasis-like inflammation (87). Obviously, 13 
intradermal injection is not appropriate for psoriasis patients, hence, like with anti-14 
miR-21, there is an urgent need for validated topical strategies to deliver miR-146a 15 
mimics to psoriatic skin in clinical trials.  16 
Interestingly, a functional polymorphism in the miR-146a gene appeared to 17 
protect against early onset of psoriasis, apparently due to the anti-inflammatory 18 
impact of elevated levels of miR-146a in keratinocytes (87). Patients with the CC 19 
rs2910164 genotype were slightly protected against psoriasis when compared to 20 
those with the GC or GG genotypes. This raises the intriguing prospect of a 21 
prophylactic regimen based on miR-146a delivery to patients at higher risk of 22 
developing the disease.     23 
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 Several miRNAs have also been reported to be downregulated in psoriatic 1 
skin, including miR-125b (90), miR-99a (91) and miR-424 (92). The roles of these 2 
and other miRNAs in psoriasis have been reviewed in detail elsewhere (93-96).  3 
 4 
MicroRNAs and cutaneous squamous cell carcinoma  5 
Non-melanoma skin cancers are the most common malignancies in the world and 6 
represent a growing public health challenge due to population ageing, UV exposure, 7 
indoor tanning and other environmental factors (97, 98). Although low-risk localised 8 
cSCC lesions can be treated by surgical methods, advanced metastatic disease has 9 
an estimated mortality rate of >70% despite various chemotherapeutic options (99, 10 
100).   11 
Early work indicated that miR-21-5p and miR-184 were elevated in cSCC 12 
compared to normal skin (101). Several independent studies have confirmed miR-13 
21-5p upregulation in cSCC (102-108). Furthermore, miR-21-3p, miR-31 and miR-14 
135b appear to be consistently elevated in cSCC (75, 106, 107, 109). With miR-21 15 
and miR-31 also being strongly linked to psoriasis as discussed above, it would be 16 
interesting to unravel the associated genomic or exposomal factors that determine 17 
the propensity of keratinocytes with elevated miR-21 or elevated miR-31 to proceed 18 
down psoriatic or cSCC paths.   19 
In contrast to the raise levels of a few miRNAs, the majority of differentially 20 
expressed miRNAs detected in cSCC were down-regulated (103, 104, 107, 109). 21 
This evokes questions about the global mechanisms underpinning miRNA alterations 22 
in cSCC and their relevance to cSCC therapy. Conceptually, reversing the overall 23 
depletion of miRNAs may offer translational benefits that exceed those of replacing 24 
individual miRNAs. However, the key factors leading to miRNA depletion in cSCC 25 
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cells have not been elucidated and the mechanistic explanations for downregulation 1 
of specific miRNAs, such as miR-124, miR-125b and miR-204 cSCC remain obscure 2 
(103, 107, 110, 111). Furthermore, although mutations in NOTCH1 and in TGFβ 3 
receptors have been defined as primary drivers of cSCC (112, 113), the relationships 4 
between impaired NOTCH1 or TGFβ receptor signalling and miRNA depletion have 5 
not been investigated.  6 
Conflicting observations have been made in relation to miR-205 in cSCC, with 7 
some studies suggesting no differential expression between normal skin and cSCC 8 
(101, 103) and others reporting elevation of miR-205 (105, 108). Notably, in an oral 9 
SCC cell line, elevated miR-205 was associated with sustained Akt signalling and 10 
cell survival via repression of SH2-containing phosphoinositide 5’-phosphatase 11 
(SHIP2) (114). Hence, in cases where miR-205 is raised in cSCC, the mechanisms 12 
of carcinogenesis may be related to the roles of miR-205 in epidermal development 13 
(52). Other miRNAs implicated in cSCC include miR-34a, miR-199a and miR-361-14 
5p, as reviewed in  (115).  15 
 16 
MicroRNAs in keratinocyte migration and wound healing 17 
Non-healing chronic wounds are also a burgeoning public health issue associated 18 
with the rising incidence of diabetes and the ageing population (116). Co-ordinated 19 
re-epithelisation of the wound surface by migrating keratinocytes is a crucial element 20 
of wound closure (117). Some miRNAs associated with psoriasis, such as miR-21, 21 
miR-203 and miR-31, have also been implicated in keratinocyte migration (72, 118, 22 
119) Raised expression of TGFβ1 in wounded mouse skin correlates with the 23 
induction of miR-21-5p in keratinocytes, and upregulation of miR-21 in the migrating 24 
cells mediates the early phase of wound contraction (72, 120). However, although 25 
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inhibition of miR-21-5p with anti-sense oligonucleotides impaired keratinocyte 1 
migration in these studies, the putative ability of a miR-21 mimic to promote wound 2 
healing was not examined. Furthermore, as highlighted above, elevated miR-21-5p 3 
has been associated with cSCC. Therefore, the translational potential of a miR-21-5p 4 
mimic in relation to wound healing remains unclear. 5 
Other miRNAs regulating keratinocyte migration include miR-483-3p, miR-24, 6 
miR-205, and miR-132 (121-125). Upregulated expression of miR-483-3p also 7 
occurs scratch-injured cultures of human keratinocytes and wounded skin in mice to 8 
sustain keratinocyte proliferation, peaking at the final stage of the wound closure 9 
process (121). Elevation of miR-24 during keratinocyte differentiation controls cell 10 
mobility and promotes differentiation by regulating the expression of several proteins 11 
associated with remodelling of the actin cytoskeleton (122). Likewise, miR-205 12 
activity has been shown to stimulate keratinocyte migration, and least partly by 13 
regulate filamentous actin polymerization and loosening cell attachment to the 14 
extracellular matrix (123). However, more recent studies from Su and colleagues 15 
suggest that raised miR-205 in the migratory front of chronic non-healing venous 16 
ulcers impairs wound healing (124). Inhibition of miR-205 derepressed integrin 17 
subunit alpha 5 (ITGA5), a component of the classical fibronectin receptor, 18 
enhancing wound closure in monolayer scratch assays and wounded mouse skin 19 
(124)., Interestingly, elevated expression of miR-210 has also been observed in 20 
keratinocytes at the edge of ischemic wound tissue (126). Consequently, a clinical 21 
trial has been launched to evaluate the relationship between miR-210 and clinical 22 
outcomes in patients with chronic venous leg ulcers (NCT02024243). Thus both 23 
miR-205 and miR-210 have potential as targets for wound therapy, and vehicles for 24 
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effective delivery of anti-miR-205 and anti-miR-210 oligonucleotides to keratinocytes 1 
will likely be required for translational purposes.   2 
 3 
Topical targeting of microRNAs in cutaneous disease  4 
Validated agents for cutaneous delivery of miRNA-directed oligonucleotides (miRNA 5 
mimics or miRNA inhibitors) for translational and clinical benefit have not yet been 6 
realised. The epidermis presents a physical and immunological barrier against the 7 
external environment and associated pathogens (127, 128). The stratum corneum 8 
(SC) provides most of the epidermal barrier function, composed as it is of non-viable 9 
keratinocyte squames embedded in a lipid-rich matrix, making it largely impermeable 10 
to water and to hydrophilic and lipophilic substances greater than 500 Da (129-131). 11 
Hence drug delivery to the viable epidermis and beyond requires optimisation of 12 
multiple parameters to secure efficient delivery without evoking an irritation response 13 
(132). We now consider emerging approaches for conveying RNA-directed 14 
oligonucleotides into the epidermis, focusing on CPPs, SNA-gold nanoparticles, 15 
deformable liposomes and LCNPs.  The transmission of miRNA-directed 16 
oligonucleotides to the epidermis is an emerging field that can take advantage of the 17 
technologies already being explore for cutaneous delivery of siRNA and other 18 
oligonucleotides. Physical approaches (microneedles, microporation) and active 19 
methods (electroporation, iontophoresis, sonophoresis) for oligonucleotide delivery 20 
into skin have been review previously by Mitragotri and colleagues (133).  21 
 22 
Cell penetrating peptides  23 
Extensive studies on the potential of cell penetrating peptides CPPs for drug delivery 24 
have been performed since the HIV TAT peptide and the Drosophila peptide 25 
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penetratin were first defined as CPPs (134, 135). Sequences presented in Table 1 1 
illustrate the diversity of selected CPPs known to traverse the SC into the viable 2 
epidermis. Broadly, CPPs are thought to enter cells through endocytosis-driven 3 
pathways or via direct translocation across the lipid bilayer, and the reader is 4 
referred to the excellent review by Bechara and Sagan for mechanistic details (136).  5 
  Early work by Khavari and collaborators indicated that conjugation of the 6 
immunosuppressant cyclosporine A (CsA) to the CPP poly-arginine (R7) enabled 7 
CsA to cross the SC of mouse and human skin (137). More recently, a SPACE (skin 8 
penetrating and cell entering) peptide was isolated by iterative selection from an in 9 
vitro phage display library and shown to facilitate delivery of CsA into porcine 10 
epidermis (138, 139). In a comparison of CPP-mediated entry of CsA into porcine 11 
skin, Mitragotri and colleagues observed little difference in performance of the 12 
SPACE peptide and R7 (140). A third peptide, TD-1, also delivered CsA into the 13 
skin, albeit with slightly lower efficiency than SPACE peptide and R7. Although all 14 
three skin-penetrating peptides (SPPs) showed minimal irritation, the toxicity profile 15 
of the SPACE peptide was lower than that of R7 and TD-1.  16 
 17 
Table 1: Sequences of selected skin penetrating peptides 18 
CPP Primary Sequence Refs. 
IMT-P8 RRWRRWNRFNRRRCR  (141) 
PepFect6 Stearyl-AGYLLGK(K(K2(tfq4)))INLKALAALAKKIL-NH2L* (142) 
Poly-Arginine (R7) RRRRRRRR (140) 
SPACE peptide AC-TGSTQHQ-CG (138) 
TD-1 ACSSSPSKHCG (143) 
*PepFect6 is stearylated analogue of transportan-10, with four trifluoroquinoline moieties attached via 19 
a lysine triplex  20 
Topical microRNA delivery for epidermal disease  
 
19 
 
The SPACE peptide has been shown to deliver covalently conjugated siRNA 1 
through the SC to silence target gene expression in mouse skin (138, 144, 145). In 2 
the rat footpad model, TD-1 transmitted siRNA throughout the epidermis and 3 
reduced expression of a target gene (143). Hence, although the use of SPACE 4 
peptide, R7 or TD-1 to deliver miRNA-directed oligonucleotides has not been 5 
evaluated to my knowledge use of these CPPs should be generalizable to miRNA 6 
mimics or inhibitors. 7 
An in silico screening approach recently yielded a 15-amino acid arginine-rich 8 
CPP, IMT-P8, penetrated cells 10 times more efficiently than TAT or a related IMT-9 
P4 peptide (141). The efficiency of IMT-P8 appears to stem not just from the helical 10 
structure it adopts but also the specific clustering of arginine residues on one phase 11 
of the helix and two critical tryptophan residues on the opposite phase (Fig. 3).  12 
The main mechanism of cell entry by IMT-P8 appears to be macropinocytosis 13 
mediated by cell-surface proteoglycans (141). Interestingly, the N-terminal portion of 14 
the IMT-P8 primary sequence (RRWRRWNRFNRRRCR) is similar to the R6W3 15 
peptide (RRWWRRWRR) reported by Sagan and colleagues (146). A comparison of 16 
the skin-penetrating capacities of these two peptides should be revealing in terms of 17 
the extent to which residues 10-15 of IMT-P8 are required for activity.  18 
In tests on shaved mouse skin, FITC-labelled IMT-P8, with or without a 19 
peptide cargo, appeared to partition predominantly to the SC (147). Relatively little 20 
distribution was evident in the bulk of the epidermis. Similarly, a large (green 21 
fluorescent protein) cargo attached to IMT-P8 appeared to be targeted mainly to hair 22 
follicles (147). Hence, utility of IMT-P8 for therapeutic miRNA transport into the 23 
epidermis will depend on the emergence of further evidence that IMT-P8 cargoes 24 
localise and function within interfollicular keratinocytes. Alternatively, IMT-P8 may 25 
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prove useful for miRNA delivery specifically to the hair follicle, for instance as an 1 
intervention for alopecia or cylindroma (148-150). 2 
 3 
 4 
 5 
 6 
Fig. 3: Representative CPPs of the IMT family. (A) Predicted helical structures of 7 
IMT-P4 and IMT-P8. (B) Helical wheel projections of IMT-P4 and IMT-P8 showing 8 
the tryptophan (W) residues positioned opposite arginines (R) in IMT-P8 but 9 
interspersed between arginines in IMT-P4.  Adapted from Gautam et al., ref. (141) 10 
with permission from Elsevier.  11 
 12 
 13 
 14 
 15 
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One limitation of the CPPs covered above is the requirement for covalent 1 
conjugation to their cargoes. In contrast, PepFect6 (PF6), developed by the Langel 2 
group, formed stable complexes with siRNA simply upon mixing the two molecules 3 
(142, 151). PepFect6 is an analogue of transportan 10 designed with an N-terminal 4 
stearyl moiety that enhances membrane insertion and four trifluoromethylquinoline 5 
derivatives to promote endosomal escape (142, 152). Recently, subcutaneous 6 
injection of PF6 CPP complexed with a miR-146a mimic was shown to suppress 7 
inflammatory gene expression in a mouse model of irritant contact dermatitis (153). 8 
There is arguably a case, therefore, for merging PF6 with SPACE peptide, R7 or TD-9 
1 in order to combine the oligonucleotide-binding capacity of PF6 with the ability of 10 
the SPPs to cross the SC into the viable epidermis. 11 
 12 
Spherical nucleic acids and gold nanoparticles   13 
Various gold nanoparticles (AuNP) are also under investigation for oligonucleotide 14 
delivery, reviewed in (154). Spherical nucleic acid nanoparticle conjugates (SNA-NC) 15 
are particularly intriguing AuNPs that have been shown to rapidly enter over 50 cell 16 
types (155). The original SNA-NC (depicted in Figure 4) consisted of a 3-dimensional 17 
(3D) gold core decorated with a densely packed shell of covalently immobilized, 18 
highly oriented oligonucleotides (156). Uptake of SNA-NC appears to occur via lipid-19 
raft–dependent, caveolae-mediated endocytosis upon binding to class A scavenger 20 
receptors (157). 21 
Work Paller and colleagues showed that such SNA-NC constructed with 22 
siRNA duplexes against the epidermal growth factor receptor (EGFR) distributed 23 
rapidly and extensively throughout the epidermis of hairless mouse skin and human 24 
skin equivalents upon topical application (158). More importantly, the expression of 25 
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 1 
Fig 4: Depiction of a spherical nucleic acid illustrating a gold core surrounded by a 2 
densely packed layer of covalently attached oligonucleotides. The core can be based 3 
on other metals or on polymers, and appears dispensable for SNA function. 4 
Reprinted with permission from Cutler et al., ref. (155). Copyright 2012, American 5 
Chemical Society.  6 
 7 
 8 
 9 
EGFR at the mRNA and protein levels was strongly suppressed in both skin models, 10 
with no apparent toxicity (158). Similar siRNA-based SNA-NCs were found to 11 
promote wound healing by downregulating ganglioside-monosialic acid 3 (GM3) 12 
synthase (159). Notably, the gold core of SNA-NC can be replaced with a 13 
biocompatible porous silica (SiO2) shell without loss of SNA functionality (160). This 14 
enhances the translational potential of SNAs given that silica can be degraded under 15 
physiological conditions (161). Furthermore, exchanging the gold core for a hollow 16 
silica shell showed that the emergent ability of SNAs to function as delivery agents is 17 
due to the dense layer of oriented oligonucleotides as opposed to the inorganic core 18 
(160). 19 
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The SNA-NC approach has been explored for targeting miRNA. Mirkin and 1 
co-workers produced SNA-NC with miR-205 mimics to facilitate miRNA replacement 2 
in prostate cancer cells (162). Although SNA-NC:miR-205 lowered the expression of 3 
a target gene by 52%, compared to a non-targeting control SNA-NC, the effects of 4 
SNA-NC:miR-205 on the transcriptome as a whole have not been established. Such 5 
insights would reveal the putative differential impact that SNA-NC:miR-205 has on 6 
miR-205-regulated transcripts. In any case, as miR-205 has been reported to 7 
promote epidermal and corneal keratinocyte migration (123) the wound healing 8 
potential of SNA-NC:miR-205 deserves exploration.   9 
Whereas the SNA-NC:miR-205 study aimed to raise effective miR-205 levels, 10 
a recent study constructed SNA-NC with antisense oligonucleotides to inhibit miRNA 11 
function. Using SNA-NC:anti-miR-99b, inflammation-related depletion of a miR-99b 12 
target gene was reversed in a mouse model of sepsis (163).  13 
These miRNA-directed SNA-NC proof-of-concept studies combined with the 14 
established abilities of topically applied SNA-NC to permeate the epidermis support 15 
the development of SNA-NC as modulators of miRNA activity in the skin. Initial 16 
efforts focussed on SNA-NC:miR-146a and SNA-NC:anti-miR-21 will be highly 17 
relevant for psoriasis. 18 
Non-covalent AuNP conjugates have also been evaluated for oligonucleotide 19 
delivery (154). Recently, a layer-by-layer approach was used to generate chitosan-20 
coated AuNPs/siRNA/chitosan formulations that penetrated porcine ear skin under 21 
iontophoresis (164). However, although AuNPs coated with chitosan or other 22 
polymer is of broad biomedical interest, there is a paucity of data regarding their 23 
utility for oligonucleotide delivery to the skin. The reader is referred to an excellent 24 
review on polymer-coated AuNPs for further insight (165).  25 
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Deformable liposomes 1 
Various “elastic” “flexible” or “ultradeformable” liposomes have recently emerged for 2 
topical delivery of therapeutic agents (166-169).  Elasticity in this context relates to 3 
the presence of both stabilizing and destabilizing molecules within a given lipid 4 
bilayer and the ability to redistribute within that bilayer (166). The exploitation of 5 
liposomes for siRNA delivery has been broadly reviewed recently by Chourasia and 6 
colleagues (170). Here, Transfersomes®, ethosomes®, transethosomes and 7 
SECosomes have been selected to illustrate the potential of deformable liposomes 8 
for topical cutaneous drug delivery.  9 
 10 
Transfersomes: The first generation of elastic vesicles developed by Cevc and 11 
colleagues were Transfersomes® consisting of phosphatidylcholine and a single 12 
chain surfactant such as sodium cholate as an edge activator (171-174). Other edge 13 
activators include Span 60/65/80, and Tween 20/60/80 (175, 176). Transfersomes® 14 
have been shown to mediate transcutaneous delivery of large macromolecules 15 
including protein immunogens (171), DNA vaccines (177, 178), insulin (173), 16 
interleukin-2 (179), hydrophobic macromolecules such as lycopene (180) and 17 
tretinoin (181). In addition, both glucocorticosteroids (182) and the nonsteroidal anti-18 
inflammatory drugs diclofenac (183, 184) and meloxicam (184-186) have been 19 
formulated in Transfersomes®. Efforts to deploy Transfersomes® specifically for 20 
inflammatory skin disease include formulation of tacrolimus for atopic dermatitis 21 
(187) but use of Transfersomes® in miRNA-directed applications has not been 22 
reported to our knowledge. The microscopic structures of Transfersomes®, 23 
ethosomes® and transethosomes are depicted in Fig. 5.  24 
 25 
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 1 
Fig 5: Transmission electron micrographs of ultradeformable liposomes that been 2 
compared directly for topical epidermal drug delivery. Reprinted from Ascenso et al., 3 
ref. (176) under the Creative Commons Attribution Non-Commercial (unported, v3.0) 4 
License. Dove Medical Press Limited.  5 
 6 
 7 
Ethosomes: Work by Touitou and collaborators led to the development of 8 
transfersome–like liposomes in which high dosing with ethanol was deployed to 9 
enhance skin permeation (188). Ethosomal lipids assembled into phospholipid 10 
bilayers in dispersions of up to 45% ethanol, and any solubilisation of the 11 
phospholipid appeared to be limited (188). A diverse range of drugs have been 12 
loaded into ethosomes® (168, 189). For psoriasis, these include methotrexate (190), 13 
tretinoin (191) and 5-aminolevulinic acid, a second-generation photosensitizer for a 14 
photodynamic therapy (192). Ethosomal entrapment has also been reported to 15 
enhance the permeation of paclitaxel across the SC and improve anticancer activity 16 
of the drug in a cSCC cell line (193). As with Transfersomes® though, the potential 17 
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of ethosomes® for oligonucleotide delivery into the epidermis remains an 1 
underexplored area of research. 2 
 3 
Transethosomes: By combining the edge activator approach of Transfersomes® 4 
with the high ethanol dose of ethosomes®, Song and colleagues designed 5 
transethosomes (175). Initial studies suggested enhance penetration of a lipophilic 6 
drug compared to Transfersomes® or ethosomes® (175). In more recent tests using 7 
porcine ear skin, Simões and colleagues found that transethosomes enabled deeper 8 
penetration of vitamin E into the viable epidermis compared to both Transfersomes® 9 
and ethosomes® (176). A similar comparison of Transfersomes®, ethosomes® and 10 
transethosomes for delivery of fluorescently-labelled miRNA inhibitors or mimics 11 
would provide a strong framework for pushing the use of these deformable vesicles 12 
for miRNA-directed therapy.  13 
Specific comparison of Transfersomes®, ethosomes® or transethosomes for 14 
oligonucleotide transport into the epidermis does not appear to have been reported. 15 
However, cationic elastic liposomes based on 1,2-dioleoyloxy-3-trimethylammonium 16 
propane (DOTAP) and sodium cholate have been shown to convey oligonucleotides 17 
into mouse epidermis (194, 195) and cadaveric human skin (196). Functional 18 
efficacy was demonstrated using antisense oligonucleotides targeting IL-13 for 19 
atopic dermatitis (194) and siRNA targeting BRAF in melanoma cells (196). Similar 20 
liposomes comprising 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 21 
ceramide in addition to DOTAP and sodium cholate have also been tested for siRNA 22 
delivery in A431 cSCC cells. Liposomes loaded with siRNA against signal transducer 23 
and activator of transcription 3 (STAT3) attenuated target gene expression in A431 24 
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cells (197). However, no permeation of porcine ear skin was observed beyond the 1 
SC unless the specimens were also subjected to iontophoresis (197).  2 
Silencing of keratin 17 (KRT17) has also been explored for anti-psoriatic 3 
potential through topical application of siRNA in a liposome-emulsion formulation 4 
though the details of the liposome were not reported (198). Importantly, however, 5 
Wang and colleagues showed siKRT17 silenced expression of KRT17 human 6 
psoriatic skin xenografts on mouse models, and this was associated with histological 7 
and clinical improvement including a reduction in epidermal thickness and 8 
substantial clearance of erythema and scales (198).   9 
 10 
SECosomes: Building on initial work showing siRNA-delivery to melanocytes using 11 
DOTAP/sodium cholate elastic liposomes (199), Lambert and co-workers combined 12 
DOTAP and sodium cholate with cholesterol as a stabilizer and 30% ethanol to 13 
enhance penetration, creating surfactant-ethanol-cholesterol-osomes (SECosomes). 14 
These SECosomes were shown to transmit siRNA to a skin-humanized mouse 15 
model of psoriasis to silence expression of human beta-defensin 2 (hBD-2, encoded 16 
by DEF4), an anti-microbial peptide that is highly over-expressed in psoriatic skin 17 
(200, 201). More recently, by altering the cholesterol composition and replacing 18 
sodium cholate with DOPE, the group produced a modified SECosome (DDC642) 19 
with increased ability to deliver siRNA into the viable epidermis of normal and 20 
psoriatic skin explants (202). The penetration of DDC642:siRNA lipoplexes into ex 21 
vivo psoriatic was associated with strong suppression of the target hBD-2 within 48 22 
h. In addition, DDC642 mediated pre-miR-145 and anti-miR-203 oligonucleotide in 23 
melanocytes and keratinocytes, respectively, to modulate target mRNA levels (202). 24 
However, anti-miR-203 had little effect on target protein levels raising questions 25 
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about the optimisation required to achieve biologically relevant miRNA-dependent 1 
outcomes with DDC642. Very recently, the group also demonstrated the ability of 2 
DDC642 complexed with siRNAs to repress targets in the reconstructed 3D psoriasis 3 
skin model available from MatTek Corporation (203). Combining siRNAs against 4 
hBD-2, thymic stromal lymphopoietin (TSLP) and KRT17 into a single DDC642 5 
formulation silenced the first two of these genes by 38% and 45%, respectively 6 
(203). However, individual siRNA formulations, including siKRT17 were more 7 
effective at reducing the levels of distinct psoriasis markers indicating the synergistic 8 
potential of a multi-targeted approach requires further evaluation.   9 
  10 
LeciPlex 11 
Liposomal vesicles in the form of self-assembled nanocarriers composed of lecithin 12 
phospholipids and cationic lipids such as didodecyldimethylammonium bromide 13 
(DDAB) or cetyltrimethylammonium bromide (CTAB) have also been developed 14 
recently for drug delivery (204, 205). These LeciPlex nanocarriers transported 15 
hydrophobic drug molecules to the SC, viable epidermis and dermis. Some evidence 16 
of in vivo drug efficacy on a rat model of acne was observed when LeciPlex vesicles 17 
were loaded with the antibacterial agent azelaic acid (204). However, the utility of 18 
LeciPlex nanocarriers for transcutaneous delivery of oligonucleotides remains to be 19 
determined. Although the abilities of DDAB and CTMA to trigger irritation raises 20 
concerns over their suitability for skin therapy (204), the low cost of DDAB is an 21 
important consideration for development of cost-effective liposomal nanocarriers, 22 
given that DDAB h 23 
as been estimated to cost 1/800 the price of DOTAP (206). Hence, the abilities of 24 
recently reported DDAB-poly(ethylene glycol) nanoassemblies to deliver miRNA-25 
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directed oligonucleotides across the SC into the viable epidermis warrants 1 
investigation (206).  2 
 3 
Liquid crystalline nanoparticles 4 
Liquid crystalline phase aggregates are lipid-based alternatives to liposomes that 5 
have received attention for topical siRNA delivery. When amphiphilic lipids are 6 
placed in an aqueous environment, they can self-organise into diverse liquid 7 
crystalline structures including the lamellar phase, cubic phase and reverse 8 
hexagonal phase (207-209), depicted in Fig. 6.  9 
Monoolein (MO; glycerol monooleate) is widely used for the generation of 10 
such liquid crystalline nanoparticles (LCNPs) and the geometries of cubic phase 11 
(cubosomes) and reverse hexagonal phase LCNPs make them particularly attractive 12 
vehicles for drug delivery and controlled release (210-213).  13 
Early work by the Bentley group found that both cubic and reverse hexagonal 14 
phases of aqueous MO LCNPs enhanced the accumulation of CsA in the epidermis 15 
and dermis of porcine skin and hairless mice (214). Addition of oleic acid (OA) 16 
enabled formation of the reverse hexagonal phase at room temperature (214). More 17 
recently, MO:OA nanodispersions incorporating cationic polymer polyethylenimine 18 
(PEI) or cationic lipid oleylamine (OAM) were shown to transmit siRNA across the 19 
SC into the viable epidermis of hairless mice and silence expression of the GAPDH 20 
target (215). Importantly, using optimised MO:OA:PEI:aqueous phase dispersions, 21 
siRNA was targeted to IL-6 in a reconstituted human psoriasis skin model, leading to 22 
a 3-fold reduction in secreted IL-6 levels (216). Interestingly, functionalisation of  23 
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 1 
 2 
Fig. 6: Liquid crystalline phase structures. Representation of the reverse hexagonal 3 
(HII), cubic, lamellar and tubular (HI) phases that can emerge depending on the 4 
relative cross-sectional dimensions of polar head groups and hydrophobic regions. 5 
Adapted from Jouhet, ref. (209) under the Creative Commons Attribution License. 6 
Frontiers Media. 7 
 8 
 9 
 10 
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MO:OA:PEI:aqueous phase nanodispersions enhanced siRNA-mediated 1 
suppression of TNFα in a phorbol ester-induced model of inflammation on hairless 2 
mouse skin (217). Together, these developments suggest Bentley’s LCNPs should 3 
prove useful in studies aimed at delivering miRNA-directed oligonucleotides, 4 
especially anti-miR-21 and miR-146a mimics, to reconstituted in vitro and mouse 5 
models of psoriatic skin. In addition, functionalisation with SPACE peptide, 6 
polyarginine or IMT-P8 may enhance the penetration of Bentley’s LCNPs into the 7 
epidermis even more than with the TAT peptide.  8 
 9 
Targeting the epidermal keratinocyte  10 
Diverse receptors including scavenger receptors, receptor tyrosine kinases, G 11 
protein-coupled receptors, integrins and TLRs can be selectively targeted for 12 
oligonucleotide delivery (21). In addition, glycosaminoglycan (GAGs) have also been 13 
targeted to promote uptake of a range of cargoes in hard-to-transduce cells (218).  14 
For specific targeting of keratinocytes, a particularly novel approach has been 15 
developed using an anti-desmoglein (Dsg) monoclonal antibodies (219). Desmoglein 16 
is a non-classical cadherin found in the desmosomes of the epidermis (220). Stanley 17 
and collaborators cloned a single-chain variable fragment (scFv) of a patient-derived 18 
anti-Dsg antibody to yield Px44. As Px44 does not include the antibody effector 19 
region, antibody-induced inflammation is avoided (219). In their studies, specific 20 
localization of a Px44-conjugated protein cargo to epidermal keratinocytes was 21 
observed after intradermal injection of the complexes into human skin xenografts on 22 
mice (219). The obvious corollary would be to determine whether Px44 can enhance 23 
the overall efficacy of epidermal oligonucleotide delivery with the vehicles surveyed 24 
above.     25 
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Conclusions 1 
In summary, we are beginning to witness the deployment of the diverse delivery 2 
vehicles surveyed above for topical delivery of siRNA, miRNA mimics and miRNA 3 
inhibitors to the epidermis (Table 2). Translating the promising initial findings to 4 
successful epidermal miRNA-dependent therapy will need to be supported with 5 
system-wide proteogenomic analyses of reconstituted human psoriatic epidermis 6 
models (221-223) exposed to the various topical vectors surveyed herein. In line with 7 
the need for affordable psoriasis treatments highlighted by the World Health 8 
Organisation (224), it will also be important to maintain cost-effectiveness for any 9 
therapies that emerge. In the meantime, clinical trials of nanoscale approaches for 10 
topical miRNA-directed therapy are likely to emerge in the near future for psoriasis, 11 
cSCC and wound healing. 12 
 13 
Table 2: Topical RNA interference for epidermal disease  14 
Target Vehicle Model Refs. 
miR-146a PepFect6/miR-146a mimic1 Mouse ear irritant contact 
dermatitis 
(153) 
EGFR SNA-NC/siRNA  Hairless mouse skin; 
reconstituted skin equivalents 
(158) 
GM3S SNA-NC/siRNA  Diabetic mouse wounds (159) 
STAT3 chitosan-coated AuNPs/siRNA/ chitosan2 Porcine ear skin (164) 
STAT3 Cationic liposomes/siRNA2 Porcine ear skin (197) 
DEFB4 DDC642 SECosome/siRNA Reconstituted psoriatic skin  (202) 
SOCS3 DDC642 SECosome/anti-miR-203 Keratinocytes (202) 
FSCN1 DDC642 SECosome/pre-miR-145 Melanocytes (202) 
IL-6 Liquid crystalline nanodispersions/siRNA Reconstituted psoriatic skin  (216) 
TNFα Liquid crystalline nanodispersions with 
TAT peptide 
Hairless mouse skin with 
chemically-induced inflammation 
 
(217) 
1
 PepFect6/miR-146a mimic delivered locally by subcutaneous injection 15 
2 Iontophoresis was required for penetration beyond the stratum corneum 16 
 17 
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